CLIMB BIO INC (CLYM) Stock News
NASDAQ:CLYM - Nasdaq - US28658R1068 - Common Stock - Currency: USD
CLYM Latest News, Press Relases and Analysis
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief...
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at...
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent,...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Climb Bio, Inc. (NASDAQ: CLYM)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Climb Bio, Inc. (NASDAQ: CLYM) on behalf of the company's shareholders. The...
Climb Bio to be Added to the Nasdaq Biotechnology Index
WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be...
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus...
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as...
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study...
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of...
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William...
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
Climb Bio to Host Virtual Investor Event on October 15, 2024
Climb Bio to Host Virtual Investor Event on October 15, 2024
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15,...